Statera Biopharma, Inc. (STAB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2021 | 28.82 Million USD | 174.52% |
| 2020 | 10.5 Million USD | 273.17% |
| 2019 | 2.81 Million USD | -52.61% |
| 2018 | 5.93 Million USD | -21.34% |
| 2017 | 7.54 Million USD | -23.55% |
| 2016 | 9.87 Million USD | -26.85% |
| 2015 | 13.49 Million USD | -99.93% |
| 2014 | 18.12 Billion USD | -42.58% |
| 2013 | 31.56 Billion USD | -6.11% |
| 2012 | 33.61 Billion USD | -0.82% |
| 2011 | 33.89 Billion USD | 124843.78% |
| 2010 | -27.17 Million USD | -100.13% |
| 2009 | 20.72 Billion USD | 8.81% |
| 2008 | 19.05 Billion USD | 68035.06% |
| 2007 | 27.96 Million USD | 206.37% |
| 2006 | 9.12 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 Q2 | 2.53 Million USD | -57.97% |
| 2022 Q1 | 6.04 Million USD | -32.9% |
| 2022 Q3 | 1.29 Million USD | -48.89% |
| 2021 Q4 | 9 Million USD | 3.58% |
| 2021 Q2 | 6.03 Million USD | 16.1% |
| 2021 Q3 | 8.69 Million USD | 44.16% |
| 2021 FY | 28.82 Million USD | 174.52% |
| 2021 Q1 | 5.19 Million USD | 31.63% |
| 2020 Q4 | 3.94 Million USD | -33.65% |
| 2020 Q1 | 111.91 Thousand USD | 0.0% |
| 2020 Q2 | 655.44 Thousand USD | 485.64% |
| 2020 FY | 10.5 Million USD | 273.17% |
| 2020 Q3 | 5.94 Million USD | 807.3% |
| 2019 Q3 | 788.03 Thousand USD | -24.85% |
| 2019 FY | 2.81 Million USD | -52.61% |
| 2019 Q1 | 988.09 Thousand USD | 0.0% |
| 2019 Q2 | 1.04 Million USD | 6.12% |
| 2018 Q3 | 1.55 Million USD | 6.26% |
| 2018 FY | 5.93 Million USD | -21.34% |
| 2018 Q1 | 2.06 Million USD | 0.0% |
| 2018 Q2 | 1.45 Million USD | -29.27% |
| 2017 FY | 7.54 Million USD | -23.55% |
| 2017 Q2 | 1.77 Million USD | -19.04% |
| 2017 Q1 | 2.19 Million USD | 0.0% |
| 2017 Q3 | 1.49 Million USD | -15.9% |
| 2016 Q3 | 1.85 Million USD | -10.34% |
| 2016 Q2 | 2.06 Million USD | -33.78% |
| 2016 Q1 | 3.12 Million USD | 0.0% |
| 2016 FY | 9.87 Million USD | -26.85% |
| 2015 FY | 13.49 Million USD | -99.93% |
| 2015 Q3 | 3.31 Million USD | 4.34% |
| 2015 Q2 | 3.18 Million USD | -18.84% |
| 2015 Q1 | 3.91 Million USD | 0.0% |
| 2014 Q3 | 3.85 Million USD | -15.75% |
| 2014 Q1 | 4.85 Million USD | 0.0% |
| 2014 FY | 18.12 Billion USD | -42.58% |
| 2014 Q2 | 4.57 Million USD | -5.74% |
| 2013 Q3 | 7.49 Million USD | -10.7% |
| 2013 Q2 | 8.38 Million USD | -4.82% |
| 2013 FY | 31.56 Billion USD | -6.11% |
| 2013 Q1 | 8.81 Million USD | 0.0% |
| 2012 Q3 | 8.06 Million USD | -14.43% |
| 2012 Q2 | 9.41 Million USD | 11.97% |
| 2012 Q1 | 8.41 Million USD | 0.0% |
| 2012 FY | 33.61 Billion USD | -0.82% |
| 2011 Q3 | 10.76 Million USD | 49.55% |
| 2011 Q1 | 7.58 Million USD | 0.0% |
| 2011 FY | 33.89 Billion USD | 124843.78% |
| 2011 Q2 | 7.19 Million USD | -5.13% |
| 2010 Q3 | 4.15 Million USD | -39.15% |
| 2010 FY | -27.17 Million USD | -100.13% |
| 2010 Q1 | 5.62 Million USD | 0.0% |
| 2010 Q2 | 6.83 Million USD | 21.4% |
| 2009 FY | 20.72 Billion USD | 8.81% |
| 2009 Q2 | 6.6 Million USD | 82.34% |
| 2009 Q1 | 3.62 Million USD | 0.0% |
| 2009 Q3 | 4.31 Million USD | -34.73% |
| 2008 Q1 | 4.74 Million USD | 0.0% |
| 2008 FY | 19.05 Billion USD | 68035.06% |
| 2008 Q3 | 4.72 Million USD | 1.08% |
| 2008 Q2 | 4.67 Million USD | -1.46% |
| 2007 Q3 | 18.63 Million USD | 112.96% |
| 2007 Q1 | 4.52 Million USD | 0.0% |
| 2007 FY | 27.96 Million USD | 206.37% |
| 2007 Q2 | 8.74 Million USD | 93.44% |
| 2006 FY | 9.12 Million USD | 0.0% |
| 2006 Q2 | 1.86 Million USD | 0.0% |
| 2006 Q3 | 1.98 Million USD | 6.76% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -4259.968% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -211.065% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 3.879% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 57.065% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -81.97% |
| Better Therapeutics, Inc. | 38.26 Million USD | 24.652% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 29.147% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -132.632% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 14.816% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 16.24% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 73.421% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -2803.832% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 11.536% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 38.597% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -2273.408% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -44.586% |
| Molecular Templates, Inc. | 63.09 Million USD | 54.305% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -106.936% |
| NexImmune, Inc. | 28.16 Million USD | -2.35% |
| Orgenesis Inc. | 45.75 Million USD | 36.994% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -12.409% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -39168.696% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -78.563% |
| Scopus BioPharma Inc. | 11.71 Million USD | -146.093% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 92.856% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -52.303% |
| Trevena, Inc. | 38.41 Million USD | 24.949% |
| Vaxxinity, Inc. | 56.05 Million USD | 48.566% |
| Vaccinex, Inc. | 23.45 Million USD | -22.914% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -2653.592% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 43.129% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -296.302% |